Recent Headlines
Within Biotechnology
Globally Recognized Agricultural Leader to Become First N.C. PSI Director
Adrian Percy, one of the world’s top leaders in the agriculture field, is set to become the first executive director of the North Carolina Plant Sciences Initiative (N.C. PSI): a world-class research and innovation effort that is poised to solve some of the world’s grandest agricultural... - September 09, 2021 - North Carolina Plant Sciences Initiative
Locus Performance Ingredients Launches New Biosurfactant-Based Personal Care Formulations to Ease Adoption of Clean Label Trend
Ready-to-use formulations utilizing novel Ferma® S sophorolipids help CPG companies replace commonly used surfactants, boost product performance and maximize sustainability. - September 09, 2021 - Locus Performance Ingredients
NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts the Efficacy of Immunotherapy in a Mouse Model of Triple Negative Breast Cancer
NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of... - September 09, 2021 - NuvOx Therapeutics
Scientists at AbboMax, Inc. Developed the New Panels of Monoclonal Antibodies to Study B- and T-Cell Lymphomas
Lymphoma is a malignant transformation of either B or T cells or their subtypes. All lymphoma subtypes combined are the seventh most common cancer in the United States. The B-cell lymphomas are types of lymphoma affecting B cells. About 85% of lymphomas are of B-cell origin. T-cell lymphomas are lymphomas that affect T cells. AbboMax has developed the new panels of monoclonal antibodies to study B- and T-cell lymphomas. - September 03, 2021 - AbboMax, Inc.
Defined Bioscience Licenses FGF2-STAB (G3) for Use in Stem Cell Media
Defined recently concluded a licensing agreement with Czech Republic-based Enantis for global use of Enantis’ patented FGF2-STAB® technology both alone and in stem cell media formulations. FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using... - August 30, 2021 - Defined Bioscience Inc.
Locus Performance Ingredients Forms Industry-Leading Advisory Board to Accelerate Global Use of Biosurfactant Innovations
The panel of top CPG and entrepreneurial executives will drive adoption of sustainable biosurfactant ingredients in product formulations. - August 26, 2021 - Locus Performance Ingredients
Omni Healthcare Communications & Res Consortium Form Alliance to Expand Medical Affairs Capabilities
Omni Healthcare Communications (Omni-HC), a US based medical communications firm delivering solutions for today’s scientific exchange challenges, is pleased to announce the formation of a strategic alliance with Res Consortium (Res) of the United Kingdom, a cross-sector leader in digital... - August 21, 2021 - Sunny Ayr Holdings
Reverie Psychedelics and Indiana Health Group Partner to Develop World-Class Psychedelic Research Center
Reverie Psychedelics (Reverie), a leading and rapidly growing psychedelic – assisted psychotherapy clinic and research organization, has further expanded its footprint and capabilities by partnering with Indiana Health Group (IHG), the largest provider of psychiatric and mental health and... - August 05, 2021 - Reverie Psychedelics
Foxx Life Sciences Celebrates Major Expansion
Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India. The new locations add four additional SUT (Single Use Technologies) Cleanrooms that will allow Foxx to meet the high demands of their biotechnology and biopharmaceutical customers. New... - August 04, 2021 - Foxx Life Sciences
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM in Ischemic Stroke
NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Stroke affects nearly 800,000 patients each year in the US. It is the fourth leading cause of death in this... - July 29, 2021 - NuvOx Therapeutics
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer Utilizing Lead Drug Candidate NanO2TM
NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing... - July 23, 2021 - NuvOx Therapeutics
Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)
Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021 - Microvascular Therapeutics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old
Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active... - July 14, 2021 - Mirror Biologics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer
Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living... - July 09, 2021 - Mirror Biologics, Inc.
Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments
Appoints CEO, Senior Executive, and Board of Directors: Peter M. Strumph, Chief Executive Officer; Brendan Classon PhD, Executive Vice President, Research and Development; Louis Demers, Vice President of Technical Operations; Matthew J. Hogan, member of the Board of Directors - July 06, 2021 - Parvus Therapeutics U.S., Inc.
Defined Bioscience Launches with $1.5M SBIR from the NIH to Advance Stem Cell Media
Defined recently received a $1.5M in Phase II SBIR award from the National Institutes of Health to develop defined media over the next two years. - July 03, 2021 - Defined Bioscience Inc.
Pepex Biomedical Receives Approval on a Series of Critical New Patents
Worldwide approval grants the Company exclusivity on a number of methods and manufacturing processes associated with its novel electrochemical biosensors. - July 01, 2021 - Pepex Biomedical, Inc.
GRG Announces 2021 Regenerative Medicine Congress in Dubai UAE
The 2nd Global Regenerative Medicine Congress will be held in Dubai 9-11 September 2021. Registration is now open. Global Regenerative Academy is a world-renowned medical society scientifically studying the clinical application of biological products in the human body. Regenerative Medicine treatments using biological products have been used to slow down the natural aging process, treat a variety of pathologies and improve the quality of life of patients. - June 28, 2021 - Global Regenerative Group
Paras Biopharmaceuticals Finland Oy Named as One of the Top Pharma Outsourcing Companies in Europe 2021
Paras Biopharmaceuticals Highlights Company Innovations that Decode and Create Biologics Medicines for Unmet Medical Needs (Pharma Tech Outlook, USA) - June 22, 2021 - Paras Biopharmaceuticals Finland Oy
Targeted Pharmaceuticals and George Mason University Announce First-Ever Preclinical Study Using Cannabinoids in an Organoid Model
Study Examines the Effects of Cannabinoids Treating Central Nervous System (CNS) Viruses including HIV Associated Dementia - June 16, 2021 - Targeted Pharmaceuticals
Locus Performance Ingredients Launches Amphi™ M: The Next Generation of Biosurfactants for Household and Industrial Formulations
TSCA-approved sophorolipid is customized to offer safe, green replacements to legacy surfactants with unmatched efficacy. - June 11, 2021 - Locus Performance Ingredients
Canada’s Leader in Cannabis Genetics Enters Medical Market
Apollo Green, Canada’s leader in cannabis genetics, announced its entry into the medical marijuana sales with unique strains of cannabis not commonly available in the Canadian marketplace. The importance of having available alternatives for pain management cannot be understated. Studies have recently shown the link between cannabis availability and reduced use of opioids. Three specialty strains of plants and seven strains of seeds will be available in Ontario, Canada. - June 08, 2021 - Apollo Green
Thrivous Launches Omega Cardioprotector Formula 2
Thrivous, the human enhancement company, has released Omega Cardioprotector Formula 2. Omega is an advanced geroprotector supplement that Thrivous develops to enhance heart function and circulation for better aging. Omega formula 2 combines geroprotector nutrients with the highest levels of... - June 03, 2021 - Thrivous
ALS TDI Launches New Young Faces of ALS Program
The ALS Therapy Development Institute's Young Faces of ALS program spreads awareness about the impact that ALS can have on young people; launch coincides with MLB's inaugural Lou Gehrig Day. - June 02, 2021 - ALS Therapy Development Institute
ICIS Names Locus Performance Ingredients Top Newcomer in the World Surfactants Awards for Biosurfactant Innovations
Company is praised for proprietary fermentation technology that produces high-purity, zero-carbon sophorolipids with maximized performance and sustainability. - May 27, 2021 - Locus Performance Ingredients
Solaris Chem Expands Its Distributors Network
Solaris Chem is a company working in the field of fine organic chemistry, synthesizing materials for the organic electronic industry since 2007. His R&D program is mainly focused on the synthesis of custom made semi-conducting polymers, fullerene derivatives and dyes specially formulated for... - May 26, 2021 - Solaris Chem Inc.
Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report
2021 Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing and Changes Since 2020 - May 25, 2021 - Life Science Strategy Group, LLC
eCTD Solutions Appoints New CEO and Changes Name to Highlight Expanded Capability
Sunny Ayr Holdings, a group of healthcare product solutions companies, is pleased to announce the change of the name of eCTD Solutions Ltd. to Omni Early Development Services and the appointment of Mark Marino, MD as Partner and Chief Executive Officer of the early product development solutions provider. - May 19, 2021 - Sunny Ayr Holdings
Healthy Cow Accepted to the Award-Winning THRIVE Accelerator Program
Healthy Cow Corporation has officially been selected to join the SVG THRIVE accelerator program from a pool of nearly 700 agtech startup applications worldwide. - May 19, 2021 - Healthy Cow
Advanced Silicon Group Closes Seed Preferred Equity Offering and Adds Alan Watson and Sarah Kelly to Board
Advanced Silicon Group, Inc. (ASG), a pioneer in silicon nanotechnology focused on developing novel biosensors, announced today the closing of a $1,020,000 seed preferred stock offering led by Cherrystone Angel Group with participation by MIT Alumni Angels of Northern California, Sidecar Angels and other private investors and the addition of two new Directors, Alan Watson, PhD, MBA and Sarah Kelly, PhD to its Board of Directors. - May 16, 2021 - Advanced Silicon Group
Cayman Develops Powerful, New Multiplex ELISA for Autoantibody Detection
Cayman Chemical's new Q-Plex™ Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardized, multiplex capabilities for the concurrent analysis of ten prominent analytes associated with rheumatoid arthritis or other autoimmune diseases. This... - May 16, 2021 - Cayman Chemical Company
CNS Healthcare Announces Launch of eReg Platform, Making Access to Regulatory Documents Available from Virtually Anywhere at Any Time
CNS Healthcare announced today the launch of eReg, an electronic regulatory binder platform. This first of its kind, web-based application will essentially replace paper binders and allow for remote monitoring capability. The proprietary platform developed by CNS Healthcare CIO & CISO, Florin... - May 14, 2021 - CNS Healthcare
Paras Biopharmaceuticals Finland Oy is Named as One of the Top 30 Admired Companies to Watch 2021
Paras Biopharmaceuticals Finland Oy, a fast-growing, biopharmaceutical technology development company, based in Oulu, Finland, announced today that it is named as one of the top 30 admired companies to watch during 2021, by CIO Bulletin, USA. - April 28, 2021 - Paras Biopharmaceuticals Finland Oy
USDA BioPreferred Program Certifies Locus Performance Ingredients Biosurfactants as 100% Biobased
Formulators can use Ferma™ S or Amphi™ M renewable sophorolipids as sustainable, high-performance alternatives to chemical surfactants in CPG formulations. - April 24, 2021 - Locus Performance Ingredients
Courage Therapeutics Awarded STTR Grant to Design Novel Anorexia Drugs
Courage Therapeutics has been awarded an STTR grant by the National Insittute of Mental Health to design novel anorexia drugs. The grant is a follow-up to research by the Cone lab at the University of Michigan that recently published in Science Translational Research that MC3R is a potential target for therapeutic development in anorexia and obesity. The effort allows for an expeditious translation of basic science into eating disorders which have remained an area of significant unmet need. - April 23, 2021 - Courage Therapeutics
Temperatures Are Rising – It's Time to Check Your Cooling Towers
As Texas and other parts of the country start to heat up, cooling towers will be in full use. Hyperion Biotechnology offers Legionella testing to monitor for bacteria growth to help reduce the risk of spread from cooling towers. - April 21, 2021 - Hyperion Biotechnology, Inc.
Adexilis Adria Opened
Adexilis Adria is the latest company established within the Adexilis network. Adexilis Adria covers the markets Croatia, Slovenia, Serbia, Bosnia Herzegovina, and Macedonia. The initial focus and products will be in Gastroenterology and Women's Health. The aim is to search for cutting edge... - April 17, 2021 - Adexilis Schweiz AG
Y-Biologics & Pierre Fabre: Confirmation of Research Partnership in Oncology
Y-Biologics and Pierre Fabre confirm their research collaboration for the development of new immunotherapies in oncology. - March 31, 2021 - Pierre Fabre
GeneThera, Inc. Wastewater Testing: a Way to Better Control the COVID-19 Pandemic
The global COVID-19 pandemic has demonstrated that neither current systems nor related technologies are capable of preventing or even successfully controlling the spread of zoonotic infectious agents. One of the prominent features of these infectious organisms is their ability to infect both people... - March 30, 2021 - GeneThera Inc.
Courage Therapeutics Raises $1M for Treatment of Anorexia Nervosa and Other Related Eating Disorders
Courage Therapeutics raised $1M towards development of treatments for eating disorders including Anorexia Nervosa, ARFID, BED and genetic obesity. The company is led by Dan Housman a parent of children with eating disorders. The round was led by Michigan Biomedical Ventures. Funding will be used to test Courage’s proprietary compounds in animal models of eating disorders. The technology is based on the research on MC3R at the University of Michigan from co-founder Dr. Roger Cone’s lab. - March 24, 2021 - Courage Therapeutics
AbboMax Introduces a Panel of Monoclonal and Polyclonal Anti-Connexin Antibodies
AbboMax introduces a panel of monoclonal and polyclonal anti-connexin antibodies. There are 21 different types of connexins which are known to exist in humans and 20 types in mice. Their abnormal expression and function are associated with human hereditary diseases. AbboMax has been developing & manufacturing high performance immunoassay reagents for many years in California. - March 15, 2021 - AbboMax, Inc.
Zifo RnD Solutions Bags the Fastest Growing Company Award at Deloitte Technology Fast 50 2020
Zifo RnD Solutions has been featuring in this list since 2012 and is the only company in India to have won this award 9 years in a row. - March 15, 2021 - Zifo
Eurofins Viracor BioPharma Launches PanCancerIQ Comprehensive Genomic Profiling Service to Advance Precision Oncology Clinical Drug Development
Eurofins Viracor BioPharma Services, a global leader in specialty bioanalytical testing services, announces the launch of their new PanCancerIQ genomic profiling test; a next-generation sequencing (NGS) service that enables comprehensive genomic profiling of tumor samples. In addition to expanding... - March 11, 2021 - Eurofins Viracor BioPharma
Intrinsic Imaging Undergoes Third FDA Inspection with No 483 Observations
Intrinsic Imaging recently underwent an extensive inspection by the U.S. Food and Drug Administration (FDA). The FDA determined Intrinsic Imaging was in complete compliance with all federal regulations and the company received zero 483 observations. This was Intrinsic Imaging's third FDA inspection and its third inspection with no findings. - March 01, 2021 - Intrinsic Imaging, LLC
AbboMax is Pleased to Introduce the Collection of Monoclonal and Polyclonal Anti-STAT Antibodies
STAT proteins (Signal transducers and activators of transcription) are cytoplasmic transcription factors that play an essential role in transmitting signals from the cellular membrane to the nucleus. Misregulation of STAT pathway frequently leads to tumorogenesis. AbboMax introduces a panel of monoclonal and polyclonal anti-STAT antibodies. - February 27, 2021 - AbboMax, Inc.
Stargardt Disease - MD Stem Cells New Treatment Improves Vision
Stem Cell Ophthalmology Treatment Study (SCOTS) show positive results in 84% of eyes. - February 18, 2021 - MD Stem Cells
Paras Biopharmaceuticals Finland Oy Affordable Healthcare Efforts Viewed in Over 90 Countries: Biosimilar Technologies Get Attention
Paras Biopharmaceuticals Finland Oy (Paras Biopharma) is a Finland-based microbial biologics company which focuses on the development of technologies for biosimilars and biologics in an efficient manner. The overall objective of Paras Biopharma is to enable economical production and future availability of affordable medicines for unmet medical needs. - February 17, 2021 - Paras Biopharmaceuticals Finland Oy
Phase One Development of Rapid COVID-19 Point of Care Test Complete
Pepex Biomedical has effectively concluded first stage development efforts including successfully demonstrating working chemistry and manufacturing functionality of its existing electrochemical biosensor. - February 11, 2021 - Pepex Biomedical, Inc.
Collection Services Provide Peace of Mind in Fight Against Legionella Bacteria
Hyperion Biotechnology expands Legionella water collection services in several California cities and other U.S. locations. Facility owners can schedule services to support their water safety plans. - February 11, 2021 - Hyperion Biotechnology, Inc.
Cayman Adds Nordic BioSite as Trusted Distributor
Cayman Chemical’s complete assay kit, protein, antibody, and biochemical portfolio is now more accessible to Denmark, Finland, Iceland, Norway, Sweden, and the Baltic countries as well as Russia through a distribution agreement with Nordic BioSite. Headquartered in Täby, Sweden, Nordic... - February 10, 2021 - Cayman Chemical Company